Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: The FUTURE study economic evaluation

Value in Health

Volumn 11, Issue 7, 2008, Pages 1022-1032

  Insinga, Ralph P ^a   Dasbach, Erik J ^a   Allen, Shannon E ^a   Carides, George W ^a   Myers, Evan R ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost; Economics; Human papillomavirus; Vaccine

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; PRIORITY JOURNAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; VAGINA CANCER; VIRUS INFECTION; VULVA CARCINOMA;

EID: 53749094013     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00342.x     Document Type: Article

References (50)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 189 : 12 19.
2. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18, L1 serology compared across anogenital cancer sites. Cancer Res 2001 61 : 1934 40.
3. Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999 37 : 3316 22.
4. Pou AM, Rimell FL, Jordan JA, et al. Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Ann Otol Rhinol Laryngol 1995 104 (10 Pt 1 758 62.
5. Rimell FL, Shoemaker DL, Pou AM, et al. Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors. Laryngoscope 1997 107 : 915 18.
6. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005 14 : 467 75.
7. Dunne EF, Markowitz LE. Genital human papillomavirus infection. Clin Infect Dis 2006 43 : 624 9.
8. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2007 57 : 43 66.
9. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007 369 : 1861 8.
10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 356 : 1928 43.
11. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18, L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006 95 : 1459 66.
12. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18), L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007 369 : 1693 702.
13. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007 13 : 28 41.
14. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007 26 : 128 39.
15. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 356 : 1915 27.
16. Koutsky LA, Ault KA, Wheeler CM, et al. A. controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002 347 : 1645 51.
17. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006 107 : 18 27.
18. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18), L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005 6 : 271 8.
19. Shi L, Sings HL, Bryan JT, et al. GARDASIL: prophylactic human papillomavirus vaccine development - from bench top to bed-side. Clin Pharmacol Ther 2007 81 : 259 64.
20. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). Oxford, UK : Oxford University Press, 2005.
21. Glick HA, Dolsi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford, UK : Oxford University Press, 2007.
22. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006 24 : 5571 83.
23. Lepkowski JM, Raghunathan TE, Solenberger P, Van Hoewyk J. A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 2001 27 : 85 95.
24. Consumer Price Index-Medical Care. U.S. Department of Labor. Bureau of Labor Statistics. 2006. Available from: http://data.bls.gov/cgi-bin/surveymost [Accessed February 15, 2007].
25. Hesterberg T, Monaghan S, Moore DS, et al. Bootstrap Methods and Permutation Tests. New York, NY : W.H. Freeman, 2003.
26. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004 364 : 1757 65.
27. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 369 : 2161 70.
28. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998 9 : 571 8.
29. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003 36 : 1397 403.
30. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002 35 (Suppl. 2 S210 24.
31. Insinga RP, Dasbach EJ, Elbasha EH, et al. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2007 2 : 15.
32. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995 33 : 2058 63.
33. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005 191 : 731 8.
34. Avances del programa de deteccion oportuna del cancer cervical en Mexico. Direccion de Prevencion y Control del Cancer en la Mujer, Centro de Equidad de Genero y Salud Reproductiva, Secretaria de Salud, D.F., Mexico. 2005.
35. Cervical cancer screening program [2005/2006]. National Health Service Cervical Screening Programme Statistics. Leeds, United Kingdom. Available from: http://www.ic.nhs.uk/pubs/csp0506 [Accessed February 9, 2007].
36. Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002 9 : 86 91.
37. National Survey of Sexual Attitudes and Lifestyles II, 2000-2001 NATSAL II; NATSAL 2000). National Centre for Social Research, United Kingdom. Available from: http://www.data-archive.ac.uk [Accessed January 26, 2007].
38. Chen CJ, Viscidi RP, Chuang CH, et al. Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: implication for optimal age of human papillomavirus vaccination. J Clin Virol 2007 38 : 126 30.
39. Touze A, de Sanjose S, Coursaget P, et al. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 2001 39 : 4344 8.
40. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16-18-31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003 89 : 1248 54.
41. Insinga RP, Glass AG, Rush BB. Pap screening in a U.S. health plan. Cancer Epidemiol Biomarkers Prev 2004 13 : 355 60.
42. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004 191 : 105 13.
43. Trends in anogenital warts and anogenital herpes simplex virus infection in the United Kingdom: 1996-2005. CDR Wkly 2006 16 : 1 4.
44. Persson G, Andersson K, Krantz I. Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Acta Obstet Gynecol Scand 1996 75 : 287 90.
45. Sastre-Garau X, Cartier I, Jourdan-Da Silva N, et al. Regression of low-grade cervical intraepithelial neoplasia in patients with HLA-DRB1*13 genotype. Obstet Gynecol 2004 104 : 751 5.
46. McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 1984 64 : 451 8.
47. Product approval information-Licensing action. U.S. Food and Drug Administration. Rockville, MD, USA. Available from: http://www.fda.gov/cber/ approvltr/hpvmer060806L.htm [Accessed February 21, 2007].
48. French KM, Barnabas RV, Lehtinen M, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex -specific pattern of vaccination in Finland. Br J Cancer 2007 96 : 514 18.
49. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007 121 : 621 32.
50. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007 56 : 1 24.